



STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: Milnacipran

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled []
Not Controlled [x]

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

- The substance is not similar to any of the substances included in the schedules to the CDSA.

Prepared by: Evelyn Soo Date: Dec 7th 2010

Verified by: Marianne Tang Date:

Approved by: DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES Date:

This status was requested by: Nacer Silarbi

Drug Status Report


Drug: Milnacipran

Drug Name Status: Milnacipran is the proper (INN) name.

Chemical Name: (±)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide

Other Names: (-)-Milnacipran, Midalcipran, Milnacipranum, Toledomin

Chemical structure:



Molecular Formula: C₁₅H₂₁N₂O

CAS-RN: 92623-85-63

Pharmacological class / Application: Serotonin-norepinephrine reuptake inhibitor (SNRI)

International status:

US: Milnacipran is not currently listed in the Schedules to the *US Controlled Substances Act* and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances Under International Control.

Canadian Status: Milnacipran is a serotonin-norepinephrine reuptake inhibitor and has been used for the treatment of depression¹ and more recently, reported in the scientific literature to be an effective treatment for chronic pain including fibromyalgia². The substance is not listed specifically in the CDSA and is not similar in structure to any of the substances included in the Schedules to the CDSA.

¹Nakagawa, A. *et al.* (2008) Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: a systematic review and meta-analysis, *CNS Drugs*, **22**:587-602.
palladium(II), *Z. Anorg. Allg. Chem.*, **631**:2575-2584.

²Kyle, JA. *et al.* (2010) Milnacipran for treatment of fibromyalgia, *Annals Pharmacother.* **44**:1422-1429.

Recommendation: Milnacipran is not included in the schedules to the CDSA and is not a controlled substance.

Date: 7 December 2010